Technical Analysis for ARDS - Aridis Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade B 9.31 -3.02% -0.29
ARDS closed down 3.02 percent on Monday, December 17, 2018, on 78 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Up
See historical ARDS trend table...

Date Alert Name Type % Chg
Dec 17 Multiple of Ten Bearish Other 0.00%
Dec 17 Inside Day Range Contraction 0.00%
Dec 17 Wide Bands Range Expansion 0.00%
Dec 14 20 DMA Resistance Bearish -3.02%
Dec 14 Wide Range Bar Range Expansion -3.02%
Dec 14 Multiple of Ten Bearish Other -3.02%
Dec 14 Wide Bands Range Expansion -3.02%
Dec 13 20 DMA Resistance Bearish -13.40%
Dec 13 1,2,3 Retracement Bearish Bearish Swing Setup -13.40%
Dec 13 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -13.40%

Older signals for ARDS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs), to treat infections. mAbs represents treatment approach that enables the human immune system to fight infections and are designed to overcome the deficiencies associated with current therapies, such as rise in drug resistance, short duration of response, negative impact on the human microbiome, and lack of differentiation among the treatment alternatives. Its product pipeline comprises of human mAbs targeting specific pathogens associated with bacterial infections, primarily hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Its lead product candidate, AR-301 targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M, mAb targeting P. aeruginosa serotype O11.
Is ARDS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.85
52 Week Low 7.59
Average Volume 4,376
200-Day Moving Average 0.0
50-Day Moving Average 11.7424
20-Day Moving Average 10.5695
10-Day Moving Average 9.022
Average True Range 0.9171
ADX 30.03
+DI 24.7326
-DI 27.2306
Chandelier Exit (Long, 3 ATRs ) 9.8687
Chandelier Exit (Short, 3 ATRs ) 10.3413
Upper Bollinger Band 13.9855
Lower Bollinger Band 7.1535
Percent B (%b) 0.32
BandWidth 64.638819
MACD Line -0.8378
MACD Signal Line -0.8107
MACD Histogram -0.0271
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.40
Resistance 3 (R3) 11.52 10.96 11.05
Resistance 2 (R2) 10.96 10.43 10.89 10.93
Resistance 1 (R1) 10.13 10.10 9.85 10.01 10.82
Pivot Point 9.57 9.57 9.43 9.50 9.57
Support 1 (S1) 8.74 9.04 8.46 8.62 7.80
Support 2 (S2) 8.18 8.71 8.11 7.69
Support 3 (S3) 7.35 8.18 7.57
Support 4 (S4) 7.23